Immugenia Obtains Pre-Seed Funding from adMare BioInnovations, ACET Capital, and Sherbrooke Innopole to Develop a Cancer Treatment Which Would Prevent Relapses

Immugenia Inc., an early-stage immune-oncology company developing a novel approach to chimeric antigen receptor (CAR) therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses, recently announced that adMare BioInnovations, ACET Capital 2, and Sherbrooke Innopole have joined forces to support the development of immunity therapy programs based on the work of Dr. Elie Haddad, clinical researcher at CHU Sainte-Justine and professor at the Université de Montréal's pediatrics department.  

Immugenia is developing a new generation of CAR therapy. Current CAR therapies involve taking immune cells from a cancer patient and modifying them to express a CAR, making it possible for them to recognize and kill cancer cells when injected back into the patient.

Immugenia is an OIS company.